

C¹
Claim 3 (Once Amended) A monoclonal antibody that immunoreacts with lipopolysaccharide (LPS) binding protein (LBP), but does not substantially inhibit LBP binding to LPS; the monoclonal antibody including a binding specificity to LBP, to denatured LBP, and to a complex containing LBP and LPS of Mab 4D7, Mab 5C5, Mab 6B6, Mab 8C9, Mab 18G4, or Mab 24B7.

C²
Claim 6 (Once Amended) A monoclonal antibody that immunoreacts with lipopolysaccharide (LPS) binding protein (LBP), inhibits LBP-mediated binding of LPS to CD14, but does not substantially inhibit LBP binding to LPS; the monoclonal antibody including a binding specificity to LBP, to denatured LBP, and to a complex containing LBP and LPS of Mab 4D7, Mab 5C5, Mab 6B6, Mab 18G4, or Mab 24B7.

Claim 7 (Once Amended) The monoclonal antibody of claim 6, wherein the monoclonal antibody inhibits LBP-mediated LPS-dependent activation of myeloid cells.

Claim 8 (Once Amended) The monoclonal antibody of claim 6, wherein the monoclonal antibody inhibits LBP-mediated LPS-dependent secretion of tumor necrosis factor from myeloid cells.

C³
Claim 12 (Once Amended) A hybridoma cell line that produces a monoclonal antibody that immunoreacts with lipopolysaccharide (LPS) binding protein (LBP), inhibits LBP-mediated binding of LPS to CD14, but does not substantially inhibit LBP binding to LPS, the monoclonal antibody including a binding specificity to LBP, to denatured LBP, and to a complex containing LBP and LPS of Mab 4D7, Mab 5C5, Mab 6B6, Mab 18G4, or Mab 24B7.